Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis

Introduction: Randomized controlled trials have investigated different first-line treatments for patients with advanced EGFR-mutated NSCLC. Nevertheless, their efficacy, in particular, the long-term overall survival (OS) benefit in Asian patients with L858R mutation, remains unclear. Methods: We per...

Full description

Bibliographic Details
Main Authors: Sik-Kwan Chan, PhD, Horace Cheuk-Wai Choi, PhD, Victor Ho-Fun Lee, MD
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small-cell lung cancer
Epidermal growth factor receptor
L858R mutation
Tyrosine kinase inhibitors
Asian
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000467

Similar Items

Similar Items